Your session is about to expire
← Back to Search
LY3972406 Dose 2 for Plaque Psoriasis
Study Summary
This trial is testing a medication called LY3972406 to see if it works and is safe for adults with a skin condition called plaque psoriasis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Which specific criteria must individuals meet to be eligible for participation in this medical study?
"To be eligible for this research study, potential participants must have a diagnosis of plaque psoriasis and fall within the age range of 18 to 75. The trial aims to recruit a total of 75 individuals with these specific criteria."
Is there an age restriction for potential participants, specifically targeting individuals above 45 years old?
"Patients aged 18 and above but under the age of 75 are eligible for recruitment in this trial."
Can you provide information about the multiple facilities within the city that are currently conducting this clinical trial?
"A total of 17 clinical trial sites, including Conquest Research in Winter Park, Center for Clinical Studies in Houston, and Oregon Dermatology and Research Center in Portland, are currently offering enrollment opportunities. Additionally, there are several other locations available as well."
Has the Food and Drug Administration officially authorized the use of Dose 1 of LY3972406?
"Considering that this is a Phase 2 trial for LY3972406 Dose 1, our team at Power rates its safety as a 2. While there is some existing data supporting safety, no evidence of efficacy has been established yet."
Are there current opportunities for patient enrollment in this clinical trial?
"According to the information provided by clinicaltrials.gov, this particular study is not currently seeking participants. Despite that, there are currently 163 other trials actively enrolling patients at this time."
Share this study with friends
Copy Link
Messenger